Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings, Inc. is a biotechnology company concentrating on developing innovative treatments for neurological disorders, regenerative medicine, and orphan diseases. With a focus on unmet medical needs, Amarantus is invested in the research and development of biological therapies, particularly in the area of neurodegenerative diseases such as Parkinson’s and multiple sclerosis. The company's portfolio includes LymPro Test® for Alzheimer's disease diagnosis, which highlights their commitment to advancing diagnostic technologies. Additionally, Amarantus is exploring the potential of MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) as a treatment for a variety of conditions, signaling its pivotal role in regenerative medicine. In the financial market, Amarantus Bioscience Holdings aims to address significant healthcare challenges, positioning itself within the biotechnology industry as a setter of future medical innovation trends.